Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Post archive for ‘Company Reports’

Portola Pharmaceuticals: 2019 Is All About the Sales Trajectory of AndexXa (PTLA, $15.46, Buy)

The launch of AndexXa is still in an early stage and there is considerable uncertainty about the sales trajectory in 2019 and beyond. This report focuses on issues that largely will determine sales

Northwest Biotherapeutics: Non-Dilutive Financing Provides Major Boost to Investment Outlook (NWBO, $0.25, Buy)

Key Points: Monetization of a UK manufacturing facility has brought in roughly $46 million of non-dilutive cash. I estimate that payment of debt obligations over the next two years will require about $10 million leaving $36 million to fund operations. At the recent quarterly burn rate of $5 million, NWBO can fund operations through mid-2020. […]

Cryoport Raises a $25 Million Warchest for Acquisitions (CYRX, $9.45, Buy)

Cryoport raises $25 million warchest for acquisiitons

Northwest Biotherapeutics: Blinded Data from DCVax®-L Phase 3 Trial is Extremely Encouraging, But We Still Need to See Unblinded Data (NWBO, Buy, $0.29)

Overview This report starts with a summary of the key aspects of my investment thinking on Northwest,updated for the just reported refresh on blinded data from the DCVax®-L phase 3 trial in newly diagnosed glioblastoma multiforme (GBM). This is followed by further discussion on why I believe the blinded data strongly hints at a medically […]

Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59)

Investment Thesis in Brief: In this report, I have put together an earnings forecast projecting EPS of (0.04) in 2019, $0.19 in 2020 and $0.33 in 2021. There are so many variables involved in my forecast that the error bars around these numbers are huge and they should be taken with a grain of salt. […]

Cryoport: Detailed Update and Updated Projections Based on 3Q Results (CYRX, Buy, $10.35)

Key Points Cryoport continued to show explosive growth in the third quarter as sales increased 76% to $5.3 million led by a 91% increase in biopharma (83% of total) sales. I am projecting a 60% increase in sales in 2019 to $30.7 million again led by a 69% increase in biopharma. (Detailed sales and a […]

Antares: Xyosted is Approved; Let the Good Times Roll (ATRS, Buy, $3.77)

Investment Thesis At Last, Three Major Product Approvals in 2018 It has been a torturous wait for Antares’ very promising pipeline to advance to commercialization, but the time has finally come. Antares and its partner Teva received approval for an AB rated generic to EpiPen on August 16, 2018 and Antares and its partner AMAG […]

Regenerative Medicine: Thoughts on How to Invest in This Dynamic New Technology

Key Investment Points of this Report Regenerative medicines promises to be a (the) major technology driving the biopharma industry in coming decades. The CAR-T products are the first commercially significant products stemming from this technology, but they are just the tip of a very large iceberg. Novartis, Gilead and Celgene have gained first mover status […]

Portola: Reiteration of Buy Recommendation (PTLA, Buy, S27.46)

Introduction This is the latest in a series of updates on Portola and is prompted by information presented in the second quarter conference call. If this is your first encounter with the Company and you would like greater detail on the company’s technology, its products and clinical trial data, you may want to read my […]

Antares: Investment Story has Shifted from Pipeline Promise to Commercial Potential (ATRS, $3.74, Buy)

Investment Summary At long last, the exciting new product potential of Antares is becoming a commercial reality. A very significant milestone for Antares was the approval gained by its distribution partner Teva in 2Q, 2016 for an AB rated generic to Imitrex (sumatriptan). This was the first of four AB rated generics that are known […]